Senses Disorder TRIZ Cases

Composite chitosan and PVA hydrogel enhances ocular bioavailability by overcoming low drug permeation in conventional eye drops.

Conjugating sulfide donors to NMDA antagonists delivers sustained hydrogen sulfide release.

Antibodies bind TREM2 epitopes to inhibit cleavage, stabilizing expression on retinal microglial cells to address dry AMD treatment gaps.

2-Oxothiazole compounds inhibit group IVa cPLA2 enzyme activity, addressing the lack of specific inhibitors for chronic inflammatory disorders.

Synthetic pyrazolopyridine agonists resolve natural protein instability by inducing receptor dimerization for tissue repair.

Class I PI3K modulators resolve off-target effects by applying local quality and parameter changes to achieve selective enzyme inhibition.

Retro-inverso alpha-MSH peptide analogs selectively bind melanocortin 1 receptors, reducing ocular and systemic toxicities in autoimmune treatments.

Genetic analysis of ERAP1 variants tailors inhibitor dosages, resolving treatment effectiveness versus personalization complexity.

Self-delivering PTEN siRNAs silence target mRNA to promote axon regeneration, overcoming delivery inefficiencies and side effects of traditional methods.

Segmenting the antibody into a small scFv enables topical penetration through the skin stratum corneum, resolving size barriers.

Acyclic compounds block Kv1.5 channels in the atrium to treat arrhythmias without causing ventricular repolarization delays.

Targeted amino acid substitutions in the IgG4 constant region prevent Fab arm exchange, ensuring stable therapeutic reliability.

Tricyclic N-heteroaryl-carboxamide derivatives containing a benzimidazole unit modulate TRPV1 receptors.

Dendrobium polysaccharides alleviate asthma symptoms by inhibiting airway remodeling and modulating immune responses to resolve inflammation inadequacy.

Stabilizer mediates solubility and stability of quinazoline derivative to resolve contradiction with therapeutic efficacy.

Quinone compounds with secondary amide side chains inhibit the redox function of Ape1, reducing tumor growth and angiogenesis.

AAV-mediated decorin delivery reduces intraocular pressure and inhibits trabecular meshwork fibrosis without systemic side effects.

Dual gene knockout of VEGFA and VHL via CRISPR modulates neovascularization while preventing cancer cell aggression.

N-hydroxyamidinoheterocycle compounds inhibit indoleamine 2,3-dioxygenase enzyme activity to restore T-cell activation in cancer treatment.

H-RN polypeptide penetrates ocular tissue barriers to maintain high drug concentration in neutral tears and aqueous humour.

A chitosan-modified hydrogel anchors sPLA2 liposomes and thiolated hyaluronic acid nanoparticles for sustained ocular drug release.

ANASA compounds selectively inhibit bacterial leucyl-tRNA synthetase enzymes, blocking essential protein synthesis pathways to treat resistant infections.

Formula I compound targets Porcn to inhibit WNT signaling, reducing cancer cell proliferation and tumor growth.

Marker-based isolation of spore-like cell subpopulations resolves control complexity in regenerative therapy.

Viral vectors deliver depolarizing light-sensitive molecules to retinal photoreceptors, resolving electrode insufficiency in blindness treatment.

Small molecule benzimidazides replace macromolecular inhibitors to reduce molecular complexity while maintaining high TNF-alpha binding inhibition.

Harderian gland lipid compounds stabilize the tear film structure to resolve dry eye symptoms that persist despite frequent artificial tear application.

Imidazole derivatives inhibit S1P lyase activity, enhancing S1P levels and reducing circulating lymphocytes to manage autoimmune disorders.

Small molecule somatostatin modulators selectively target SSTR2 receptors to inhibit hormone secretion with improved water solubility.

Porous affinity matrix extracts pro-inflammatory cytokines from tear fluid via reversible compression, eliminating drug side effects.

Polysaccharide-coated lipid nanoparticles protect genetic material from enzymatic degradation while enabling high transfection efficacy in retinal cells.

Ultracentrifugation isolates healing factors from lipids to enable scalable, virus-safe production of eye drops.

EMCN inhibitor targets endothelial cells to reduce neovascularization, addressing specificity issues in treating age-related macular degeneration.

Phenolic compounds in palm fruit juice mitigate mitochondrial DNA damage caused by antiretroviral nucleoside reverse transcriptase inhibitors.

A pharmaceutical composition containing cholinesterase inhibitors and muscarinic agonists stimulates lacrimal gland secretion to restore tear volume.

Recombinant Factor I derivatives enhance C3b-inactivating activity to reduce inflammation and tissue damage in age-related macular degeneration.

Adeno-associated virus vectors deliver synthetic RNA molecules to silence mutant gene expression while preserving normal photoreceptor function.

Novel dihydrothienopyrimidine sulfoxides featuring heterocyclic or heteroaryl R3 substituents expand the therapeutic scope of PDE4 inhibitors.

An aglycosylated anti-IL-6 antibody raises serum albumin levels and improves coagulation profiles in patients with elevated inflammatory markers.

A trifunctional bispecific antibody coordinates immune responses by binding B cells, T cells, and Fc receptors.

Ligand-conjugated interfering RNA targets ocular tissues via LDLR binding, resolving delivery inefficiency and off-target effects.

Gold nanorods enable targeted optical delivery of exogenous molecules to specific cells via photothermal membrane perforation.

Shear-thinning polyaphron dispersions improve drug retention and efficacy while reducing application frequency.

D-glutamic acid prevents underlying cellular damage in keratinocytes and fibroblasts, offering a stable alternative to conventional symptomatic relief agents.